FDA Clocks Time for UNLOXCYT Patent Boost
Published Date: 4/16/2026
Notice
Summary
The FDA has set the official review period for UNLOXCYT, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind UNLOXCYT and anyone interested in patent rules. If you think the dates are wrong or want to challenge the company’s effort during review, you have until mid-2026 to speak up—potentially impacting patent length and market exclusivity.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
UNLOXCYT regulatory review length set
The FDA determined the regulatory review period for UNLOXCYT is 2,000 days total: 1,289 days in the testing phase and 711 days in the approval phase. This establishes the maximum possible patent extension window for the patent holder; the applicant has requested 196 days of patent term extension.
Public deadlines to challenge dates or due diligence
Anyone who believes the published dates are wrong must submit comments asking for redetermination by June 15, 2026. Any interested person may petition FDA about whether the applicant acted with due diligence during the regulatory review period by October 13, 2026.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-09767, Oscar Bobo: Final Debarment Order
Oscar Bobo is officially banned for 5 years from importing any drugs into the U.S. because he repeatedly brought in mislabeled medicines that don’t follow FDA rules. He didn’t respond to the FDA’s warning, so the ban started on May 15, 2026. If he wants to end the ban early, he can apply anytime, but must follow special rules to keep his info private.
2026-09533, Biomarker Incubator: Urinary Kidney Safety Biomarkers; Request for Information
The FDA wants your help to improve tests that spot kidney damage caused by medicines. They’re asking researchers, doctors, and companies to share data by July 13, 2026, so they can make these kidney safety markers better and faster. This could lead to safer drugs and smarter health checks, benefiting patients and the medical community alike.
2026-09508, Azodicarbonamide (ADA); Request for Information
The FDA is asking for info about azodicarbonamide (ADA), a chemical used in some foods and food packaging, to check if it’s still safe. Food makers, scientists, and anyone with data should share what they know by July 13, 2026. This review could lead to changes in how ADA is used, affecting food companies and possibly costs down the line.
2026-09543, Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Experience Reporting
The FDA wants your thoughts on how drug companies report problems after their products hit the market. This update affects drug makers and helps keep medicine safe by improving how side effects are tracked. You’ve got until July 13, 2026, to share your comments—no cost to join, just your voice!
2026-09544, Modified Risk Tobacco Product Application: Renewal Applications for VLN® King and VLN® Menthol King, Cigarette Products Submitted by 22nd Century Group Inc.
The FDA is inviting the public to comment on the renewal of special approval for two cigarette products by 22nd Century Group Inc. These products claim to lower health risks compared to regular cigarettes. If renewed, the company can keep marketing them this way, with the comment period starting May 13, 2026.
2026-09507, Butylated Hydroxytoluene (BHT); Request for Information
The FDA wants to know more about how butylated hydroxytoluene (BHT), a chemical used in food and food packaging, is being used and if it’s still safe. They’re asking companies, scientists, and the public to share any info by July 13, 2026. This could lead to changes in rules that affect food makers and might impact what’s allowed in your snacks and packaging.
Previous / Next Documents
Previous: 2026-07421, Agency Information Collection Activities; Proposed Collection; Comment Request; Importation of Prescription Drugs
The FDA wants your thoughts on how they collect info about importing prescription drugs. This affects drug companies and anyone involved in bringing meds into the U.S. You’ve got until June 15, 2026, to share your comments—no cost to join, just your voice! It’s all about making sure the rules stay clear and helpful.
Next: 2026-07423, Agency Information Collection Activities; Proposed Collection; Comment Request; Orphan Drugs
The FDA wants your thoughts on how it collects info about orphan drugs—special medicines for rare diseases. They’re asking for comments by June 15, 2026, to make sure the process is clear and not too complicated. This helps keep things running smoothly without extra costs or delays for drug makers and patients.